Akshat Jain: Reassessing Cost-Effectiveness of Iron Deficiency Anemia Treatments
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about his recent article published in Blood Advances:
”Happy to share our New Publication in Blood Advances.
We address an important question in the management of iron deficiency anemia (IDA) and the interpretation of health economics bringing global burden of this significant health morbidity per World Health Organization.
While recent modeling suggested that first-line intravenous (IV) iron may be the most cost-effective strategy for women with heavy menstrual bleeding, our publication emphasizes that cost-effectiveness is only as strong as the assumptions and comparators included in the model and real world avalaibility of these treatment options.
Key scientific messages from this publication:
- Calls for cautious interpretation of cost-effectiveness models that rely on uncertain assumptions regarding adherence, quality-of-life estimates, and long-term outcomes.
- Highlights the omission of ferric carboxymaltose (FCM)—one of the most widely used contemporary IV iron formulations—which may substantially influence both healthcare costs, new risks of bone health and patient outcomes.
- Brings a global health perspective to the discussion, recognizing that in many low- and middle-income countries, oral iron remains the only practical and affordable treatment option because of resource and infrastructure limitations.
- Encourages future comparative economic studies that include contemporary IV iron formulations while accounting for regional healthcare realities before translating modeling results into universal clinical policy.
Scientific progress depends not only on new discoveries but also on thoughtful evaluation of the evidence that guides patient care.
As healthcare systems increasingly rely on economic modeling to shape policy, ensuring that these analyses are comprehensive, globally relevant, and clinically applicable is essential.
Proud to contribute to this important discussion in hematology and healtheconomics.”
Title: Iron Deficiency: Cost-Effectiveness and Global Applicability
Authors: Akshat Jain
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 18, 2026, 17:48Ronak H. Mistry: Updated ASH Guidelines Bring New Focus to Iron Deficiency
-
Sep 18, 2026, 17:32Hassan Kawtharany: New Ferritin Cutoffs for the Diagnosis of Iron Deficiency With or Without Anemia
-
Sep 18, 2026, 17:20Abhishek G P: GAVE as an Important Cause of Chronic Gastrointestinal Blood Loss
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH